Drug Trial Radar · NCT00559988
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
Last checked: Nov 19, 2026Latest source record: Dec 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,718
Actual
Start
Feb 2008
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Biotronik, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implanted dual-chamber defibrillators or cardiac resynchronization therapy devices.
Conditions
- Atrial Fibrillation
- Atrial Flutter
- Stroke
- Embolism, Systemic Arterial
- Major Bleeding
Interventions
Home Monitoring Guided OACDrug
Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy. OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Physician-Directed OACDrug
Patients will receive physician-directed anticoagulation therapy based on conventional criteria. OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Primary Endpoint: Kaplan-Meier Estimate of Patients Without a Stroke, Systemic Embolism, or Major BleedTime frame: From date of enrollment until date of primary endpoint event, assessed up to study exit, with a mean treatment duration of 2.0 years
Locations
80 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Anaheim, California
Site not named
Fremont, California
Site not named
Santa Barbara, California
Site not named
Torrance, California
Site not named
Ventura, California
Site not named
Aurora, Colorado
Site not named
Boulder, Colorado
Site not named
Newark, Delaware
Site not named
Davenport, Florida
Site not named
Daytona Beach, Florida
Site not named
Kissimmee, Florida
Site not named
Melbourne, Florida
Site not named
Sarasota, Florida
Site not named
St. Petersburg, Florida
Site not named
Zephyrhills, Florida
Site not named
Chicago, Illinois
Site not named
Elk Grove Village, Illinois
Site not named
Maywood, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Valparaiso, Indiana
Site not named
Shawnee Mission, Kansas
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Owensboro, Kentucky
Site not named
Hammond, Louisiana
Site not named
Lafayette, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Bangor, Maine
Site not named
Lewiston, Maine
Site not named
Cumberland, Maryland
Site not named
Boston, Massachusetts
Site not named
Burlington, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Bay City, Michigan
Site not named
Lansing, Michigan
Site not named
Lapeer, Michigan
Site not named
Saginaw, Michigan
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.